Lupin Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Lupin Ltd. from all sources in a single place.

Load latest

Lupin Ltd.

30 Nov 2024

1969.50

-1.07%

Company Update

LUPIN LTD. - 500257 - Clarification /Confirmation On The News Item Appearing In Www.Business-Standard.Com

BSE India

Clarification / confirmation on the news item appearing in www.business-standard.com

pdf

Lupin Ltd.

29 Nov 2024

1969.50

-1.07%

Company Update

LUPIN LTD. - 500257 - Clarification sought from Lupin Ltd

BSE India

The Exchange has sought clarification from Lupin Ltd on November 29, 2024, with reference to news appeared in www.business-standard.com dated November 29, 2024 quoting "Lupin shares gain 3% after USFDA approves type-2 diabetes drug; details" The reply is awaited.

Lupin Ltd.

29 Nov 2024

1969.50

-1.07%

Lupin shares gain 3% after USFDA approves type-2 diabetes drug; details

Business Standard

Lupin share price gained after the company announced that it has received tentative approval from the United States Food and Drug Administration (US FDA)

Lupin Ltd. is trading below its 30 day SMA of 1972.3

Lupin Ltd.

28 Nov 2024

1969.50

-1.07%

Company Update

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation about participating in the Analyst/Institutional Investors Meet.

pdf

Lupin Ltd.

27 Nov 2024

1969.50

-1.07%

Corp. Note

LUPIN LTD. - 500257 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

Intimation regarding issuance of duplicate share certificates.

pdf

Lupin Ltd.

25 Nov 2024

1969.50

-1.07%

Lupin recalls over 600,000 bottles of hypertension drug in US: USFDA

Business Standard

Drug firm Lupin is recalling over six lakh bottles of a medication indicated for high blood pressure in the US due to deviation from current good manufacturing practices (CGMP), according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA), stated that Dr Reddy's Laboratoties is also recalling a product in the US due to a manufacturing issue. Baltimore-based Lupin Pharmaceuticals Inc, a subsidiary of Mumbai-based Lupin, is recalling 6,16,506 bottles of Ramipril capsules in strengths of 2.5 mg, 5 mg and 10 mg, the US health regulator said. The affected lot is manufactured at Lupin's Goa-based manufacturing facility, it stated. The company is recalling 1,12,770 bottles of 2.5 mg tablets; 1,46,322 bottles of 5 mg tablets and 3,57,414 bottles of 10 mg tablets, it said. The US health regulator noted that the company is undertaking Class II voluntary recall due to "CGMP Deviations: Active pharmaceutical ingredient was sourced from an